ArticleFrontiers in oncology2026
ZNF473 as a biomarker and potential therapeutic target in cancer: integrated bioinformatics and experimental evidence with a focus on hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Zinc finger protein 473 (ZNF473) has been implicated as a regulatory factor in several cancer types; however, its precise biological functions and underlying mechanisms remain incompletely defined. This study aimed to evaluate the biological and clinical relevance of ZNF473 in cancer through integrated bioinformatics analyses in combination with cell-based experimental validation. Methods: ZNF473 function was investigated using comprehensive bioinformatics approaches in combination with Results: ZNF473 exhibited differential expression across a range of normal tissues and malignancies and was significantly upregulated in more than 10 cancer types. Analyses based on the Tumor-Immune System Interaction Database indicated that ZNF473 expression correlated with both molecular and immune subtypes in multiple cancers. Receiver operating characteristic analyses yielded an area under the curve exceeding 0.7 in 19 cancer types, suggesting moderate diagnostic performance. Kaplan-Meier and Cox regression analyses identified significant prognostic associations in four cancer types, with hepatocellular carcinoma (HCC) demonstrating the most consistent clinical relevance in this dataset. In HCC, elevated ZNF473 expression was associated with unfavorable clinicopathological features, altered immune cell infiltration profiles, and enrichment of PI3K/AKT-related signaling pathways. Functional assays further showed that ZNF473 knockdown reduced cellular proliferation and migration, together with decreased levels of phosphorylated AKT (p-AKT), in liver tumor models. Conclusion: These findings support the role of ZNF473 as a clinically relevant biomarker candidate across cancers and suggest its involvement in HCC progression, potentially through activation of the AKT signaling pathway. The HCC-related findings should be interpreted cautiously, as further validation in established HCC models remains necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.